Summary:
In adults with inadequately controlled type 2 diabetes on daily basal insulin therapy, once-weekly IcoSema (a combination of basal insulin icodec and semaglutide) significantly improved glycemic control and reduced weight compared to once-weekly icodec alone, though it was associated with mild gastrointestinal side effects such as nausea.
| PICO | Description |
|---|---|
| Population | Adults with inadequately controlled type 2 diabetes on daily basal insulin therapy (HbA1c >7.0% to ≤10.0%). |
| Intervention | Once-weekly IcoSema, a combination of basal insulin icodec and semaglutide (GLP-1 receptor agonist). |
| Comparison | Once-weekly icodec (basal insulin) monotherapy. |
| Outcome | IcoSema significantly reduced HbA1c levels by -1.68% compared to -1.31% with icodec alone and also resulted in a greater reduction in body weight (-4.12 kg vs. -0.41 kg). The combination therapy was associated with improved glycemic outcomes but reported mild gastrointestinal side effects such as nausea. |
Source: Chantal Mathieu, et al. “Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.” Read article here.
